Ventana Medical Systems’ (Ventana) CONFIRM anti-CD79a (SP18) Rabbit Monoclonal Primary Antibody is intended for the detection of CD79a in normal and neoplastic human tissues. Anti-CD79a is directed against a protein expressed on the surface of B lymphocytes at all stages of maturation, from B lymphocyte precursors through plasma cells. Expression of CD79a may aid in the identification of B cell lineage in malignant lymphomas. The antibody is intended for qualitative staining in sections of formalin-fixed, paraffin-embedded tissue.
This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information and proper controls.
This antibody is intended for in vitro diagnostic (IVD) use.